Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients (NCT00082628), a randomized phase 3 study. The primary outcome is Treatment Period I: Change From Baseline in Absolute Area of Visceral Adipose Tissue (VAT) at Week 12.

2. Clinical Question

3. Trial Design

The registry describes a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study sponsored by EMD Serono. The study is listed as completed, with enrollment of 326. The recorded start date is 2004-05-28 and the primary completion date is 2005-09-28. The official title describes a study of the safety and efficacy of Serostim® (r-hGH) for treatment and maintenance of HIV-associated adipose redistribution syndrome.

In Treatment Period I, participants received either matching placebo daily for 12 weeks or Serostim® by subcutaneous injection at a maximum dose of 4 mg per day based on body weight for 12 weeks. The primary endpoint compares these initial-period groups at Week 12. The registry identifies the overall allocation as randomized but does not report the allocation ratio or the method used to generate or conceal the allocation sequence.

The record also describes later regimens. Participants initially assigned to Serostim® 4 mg were assigned in Period II to alternate-day placebo or alternate-day Serostim® 2 mg for 24 weeks. Participants initially assigned to placebo continued placebo for 12 weeks and then received Serostim® 4 mg daily for 12 weeks. The posted primary result concerns Treatment Period I, not a randomized comparison across all these later sequences. Period II includes changing treatments and therefore addresses a different time course and set of questions.

Enrollment is not the same as the number analyzed for a particular outcome. For the primary endpoint, the registry’s modified ITT definition required baseline and at least one post-baseline efficacy measurement in Treatment Period I, and the analyzed counts were 74 for placebo and 210 for Serostim® 4 mg. The reason participants were not included in each outcome analysis is not reported in the registry record. The protocol’s original sample-size justification and the detailed randomization procedures are also not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Treatment Period I (Week 1 to Week 12)

Reasons for not completing this period:

Treatment Period II: Week 12 to Week 36

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: The modified ITT Population was defined as all subjects who had a baseline and at least one post-baseline efficacy measurement in treatment period I. Here "Overall Number of Participants Analyzed" signifies those subjects who were evaluable for this outcome.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: The modified ITT Population (ITT) for Period I was defined as all subjects who had a baseline and at least one post-baseline efficacy measurement.

6. Primary Endpoint

The registry lists the primary outcome as Treatment Period I: Change From Baseline in Absolute Area of Visceral Adipose Tissue (VAT) at Week 12, measured over Baseline, Week 12.

The primary endpoint was change from baseline to Week 12 in absolute area of visceral adipose tissue, measured in square centimeters. VAT is the visceral compartment of abdominal fat. The registry describes measurement by cross-sectional computed tomography at the level of the L4-5 inter-vertebral disk, where the scan was intended to assess abdominal fat area and the distribution between visceral and subcutaneous compartments.

A change score expresses how a measured value differs from its baseline value over the specified period. A negative mean change indicates that the measured area was lower at follow-up than at baseline on average; a positive mean change indicates an increase on average. For the posted primary endpoint, the Serostim® group mean change was -32.6 and the placebo group mean change was 0.5. The recalculated difference is expressed as Serostim® minus placebo, so its negative direction represents a lower mean change in the Serostim® group.

VAT was used as the primary measure because the stated objective was to assess whether Serostim® reduced the abnormal fat accumulation associated with HARS. CT provides an image-based measurement of the abdominal fat compartments. A measured change in VAT is an endpoint result, not a direct measure of every aspect of the syndrome, patient experience, or long-term health. The registry record does not report a threshold for a clinically important change in VAT, so the clinical importance of a particular numerical difference cannot be determined from the endpoint values alone.

7. Results Posted in the Registry

• Period I: Serostim® 4 mg: mean -32.60 versus 0.50 on control; difference -33.10 (95% CI -42.48 to -23.72), standardized effect d = -0.89; z-test p = <0.001.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Treatment Period I: Change From Baseline in Trunk Fat at Week 12

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Period I: Serostim® 4 mg: mean -2.20 versus 0.20 on control; difference -2.40 (95% CI -2.77 to -2.03), standardized effect d = -1.49; z-test p = <0.001.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the mean is statistically lower for Period I: Serostim® 4 mg than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

Change From Baseline in Patient Reported Outcome of Body Image Distress at Week 12

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Period I: Serostim® 4 mg: mean 0.10 versus 0.23 on control; difference -0.13 (95% CI -0.51 to 0.25), standardized effect d = -0.08; z-test p = 0.504.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Period I: Serostim® 4 mg and the control. The interval gives the range of effects that remain compatible with the data.

Treatment Period I: Change From Baseline in Non- High-density Lipoprotein (Non-HDL) Cholesterol at Week 12

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Period I: Serostim® 4 mg: mean -13.00 versus -2.80 on control; difference -10.20 (95% CI -18.22 to -2.18), standardized effect d = -0.29; z-test p = 0.013.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the mean is statistically lower for Period I: Serostim® 4 mg than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

The secondary endpoints examine additional domains: trunk fat, patient-reported body image distress, non-HDL cholesterol, and a Period II VAT-based failure outcome. Together, these outcomes broaden the study beyond the primary CT-based VAT measure, but they do not all represent the same biological or participant-centered construct. Their differing scales and follow-up contexts mean they should be interpreted individually rather than combined into a single overall effect.

The posted secondary results show a pattern in which some measures have group contrasts that are more distinct from zero than others, while the body image distress comparison is less conclusive. This does not overturn or independently confirm the primary VAT finding. Rather, it indicates that results across the measured domains are not interchangeable: a difference in a body-composition measure does not necessarily imply a parallel change in a patient-reported measure or a blood lipid measure.

The registry lists four secondary outcomes, but the posted endpoint summaries and analyses do not provide a uniform adjusted inferential framework for all of them. The secondary comparisons are unadjusted, and the record does not report a multiplicity strategy. When several outcomes are tested, the chance of at least one apparently noteworthy result can increase. Without a reported adjustment or prespecified hierarchy, individual secondary p-values carry less weight than the primary comparison and should be treated as supportive or exploratory rather than definitive.

Secondary endpoints can still be informative. They can show whether findings appear confined to the primary measurement or extend across other measured domains, and can help identify questions for further study. Their interpretation depends on measurement quality, missingness, analysis choices, and whether the outcomes were designated in advance. The registry record does not report enough detail to resolve all those considerations. Accordingly, the overall secondary pattern provides context for the primary result, but does not establish a broad effect across every outcome or a coherent participant-level benefit.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Treatment Period I: Change From Baseline in Trunk Fat at Week 12
• Change From Baseline in Patient Reported Outcome of Body Image Distress at Week 12
• Treatment Period I: Change From Baseline in Non- High-density Lipoprotein (Non-HDL) Cholesterol at Week 12
• Treatment Period II: Failure Rate at Week 36 Based on Visceral Adipose Tissue (VAT) For Subjects Who Received Serostim® 4 mg in Period I

9. Statistical Interpretation

10. Statistical Methods Explained

What does the mean change represent?

The primary outcome is continuous: it is measured on a numerical scale, and the registry reports the mean and standard deviation for each group. Mean change is the average of participants’ differences between baseline and the specified follow-up. It gives a concise description of the group’s central change, but it does not convey the full distribution of individual changes. The posted mean changes are -32.6 for Serostim® and 0.5 for placebo, with standard deviations of 37.9 and 34.5, respectively.

A mean difference compares the two group means. In the recalculation, the contrast is defined as the Serostim® mean minus the placebo mean, giving -33.1. The negative sign is meaningful only alongside that contrast direction and the endpoint definition. Since lower change represents a greater decrease in the measured area, the negative estimate describes a lower average change in the Serostim® group than in the placebo group. This is a statement about the observed group averages, not about each participant.

What does the registry’s analysis do?

The registry reports a nonparametric ANCOVA model for the primary comparison and gives p < 0.001. ANCOVA is a general statistical approach that compares groups while accounting for one or more covariates. In a randomized trial, baseline measurements are often relevant covariates when the outcome is measured at follow-up. The registry record does not report the covariates, model specification, test statistic, or an adjusted effect estimate and confidence interval for this analysis. The word nonparametric indicates that the reported method is not presented as a standard parametric ANCOVA, but the exact implementation is not reported in the registry record.

The p-value is a result from that sponsor-reported analysis. It is a tail probability calculated under a null model and the analysis assumptions; it is not a probability that the observed result occurred “by chance” in an everyday sense. It also does not indicate the probability that a treatment effect exists. Statistical significance and effect magnitude are different: the p-value addresses compatibility with a null comparison, while the mean difference gives an estimate on the VAT measurement scale.

What is the unadjusted recalculation?

The recalculated comparison uses the posted group means and participant counts to describe a simple, unadjusted difference between the group summaries. Its 95% confidence interval is -42.48 to -23.72. This calculation does not reproduce the nonparametric ANCOVA model. The unadjusted result can help readers understand the scale and uncertainty of the contrast, but it should not be mistaken for the sponsor’s adjusted analysis. The registry’s reported method remains the trial’s own analysis.

The standard deviation describes dispersion of individual measurements around a group mean. It is not the same as the standard error, which describes the sampling uncertainty of an estimated mean. A group can have substantial participant-to-participant variation while still having a more precise mean estimate when more participants contribute data. In this comparison, the analyzed counts were 74 for placebo and 210 for Serostim®; the unequal group sizes are part of the precision context for the unadjusted contrast.

Why does distribution matter?

General statistical explanation: methods based on normal distributions can be sensitive to skewness, extreme observations, or unequal variability, depending on the model and sample. Nonparametric approaches can reduce reliance on particular distributional assumptions, although their interpretation depends on the exact test or model used. Over-dispersion, in general, means that observed variability exceeds what a specified model expects; if ignored, uncertainty can be understated. The registry does not report enough model detail to determine whether over-dispersion was assessed or how it was handled in the sponsor analysis.

General explanation: a confidence interval describes a range of values compatible with the data and the procedure used to calculate it. Repeated use of a procedure would produce intervals that cover the fixed target parameter at the stated rate under the procedure’s assumptions. It is not a range containing a stated proportion of individual participant outcomes, and it does not assign a probability to the fixed effect after the data have been observed. Here, the interval belongs to the unadjusted recalculation and should be interpreted with that distinction in mind.

What population is represented?

The registry defines the primary modified ITT population as subjects with baseline and at least one post-baseline efficacy measurement in Treatment Period I who were evaluable for the outcome. This differs from simply describing everyone enrolled or randomized. The primary endpoint counts were 74 and 210. The exact reasons for the difference between enrollment, randomized groups, and endpoint-evaluable counts are not reported in the registry record. If outcome availability is related to participants’ characteristics or outcomes, an analysis restricted to observed measurements may not fully preserve the balance created by randomization; the record does not report enough information to assess that possibility.

Interpretation therefore combines several pieces: the definition and direction of the VAT measure, the group means and standard deviations, the unadjusted contrast and its interval, and the sponsor-reported nonparametric ANCOVA p-value. Each has a distinct role. None alone provides the full distribution of outcomes, answers questions about unreported follow-up, or establishes clinical importance.

11. Confidence Intervals and Precision

The recalculated mean difference in Week 12 VAT change is -33.1 square centimeters, with a 95% confidence interval from -42.48 to -23.72. In practical terms, the interval describes the uncertainty around the unadjusted average contrast using the posted group summaries and the calculation’s assumptions. It is compatible with a range of negative differences rather than one perfectly known value. Across that interval, the contrast remains in the direction of a lower mean change in the Serostim® group than in the placebo group.

A confidence interval is not a prediction interval for individual participants. The group standard deviations, 34.5 and 37.9, describe the observed spread of individual changes around the means; the confidence interval instead concerns uncertainty in the estimated difference between group means. The dispersion in the individual values can be much wider than the uncertainty interval for a group contrast, especially when many observations contribute to estimation.

The interval is from an unadjusted recalculation, not the nonparametric ANCOVA result reported by the registry. The registry does not report an adjusted effect estimate or confidence interval for its model. Consequently, the recalculated interval should not be attributed to the sponsor’s model or treated as its adjusted uncertainty estimate. The sponsor-reported p-value is p < 0.001, while the unadjusted interval describes a distinct calculation based on the posted summary statistics.

Precision is also specific to the analyzed population and endpoint. Counts were 74 for placebo and 210 for Serostim® in this outcome analysis. The registry record does not report a clinically important threshold for VAT change, so the interval cannot by itself establish whether values within its range represent meaningfully different outcomes for participants. It quantifies statistical uncertainty in the unadjusted contrast, not uncertainty about every broader clinical interpretation.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The planning figures are participants per arm, not total events. They are retrospective planning illustrations based on the observed effect, not the trial’s original design calculation. The stated assumptions are a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; each scenario targets a stated fraction of the observed effect. The original protocol’s sample-size assumptions and justification are not reported in the registry record.

The 80% power column gives the illustrative number of participants per arm for a design that would have an 80% chance of detecting the chosen effect under the stated assumptions, if that effect and the model assumptions were correct. The 90% power column gives the corresponding per-arm number for a higher chance of detecting that effect. For example, planning for 75% of the observed primary effect gives 35 participants per arm for 80% power and 47 participants per arm for 90% power.

The figures change with the assumed effect size. Planning for a smaller fraction of the observed effect requires more participants per arm than planning for the full observed effect, because smaller differences are harder to distinguish from sampling variation. This is an important sensitivity consideration: the observed effect is one estimate from one trial and may not be the effect a future study should expect.

These figures are not observed power. They are planning illustrations, not evidence about the probability that the completed trial detected its true effect, and they do not replace the trial’s own design rationale. The curve’s general role is to make the relationship between assumed effect size and required sample size visually interpretable; the numerical planning values remain dependent on the stated assumptions.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, Δ is the difference in means to detect and σ is the common standard deviation.

Worked calculation for this trial

1. Observed difference Δ = -33.100; pooled standard deviation σ = 37.050.
2. n = 2 × (1.96 + 0.842)² × 37.050² / -33.100² = 19.7, rounded up to 20 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
delta <- -33.1                      # observed difference in means
sigma <- 37.0498006809275                     # pooled standard deviation
n_per_arm <- function(power, frac = 1) {
  ceiling(round(2 * (z_a + qnorm(power))^2 * sigma^2 / (delta * frac)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (t-based, so very slightly larger)
cat("power.t.test:", round(power.t.test(delta = delta, sd = sigma, power = 0.80)$n, 1), "\n")

# Simulation: exact two-sample t-test using simulated means and variances
set.seed(82628)
n    <- n_per_arm(0.80)
reps <- 20000
m_diff <- rnorm(reps, delta, sigma * sqrt(2 / n))             # difference in sample means
s2     <- sigma^2 * rchisq(reps, 2 * (n - 1)) / (2 * (n - 1))   # pooled sample variance
tstat  <- m_diff / sqrt(s2 * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(tstat) > qt(0.975, 2 * (n - 1))), reps))

Output from running the code

100% of observed effect: n per arm = 20 (80% power), 27 (90% power)
 75% of observed effect: n per arm = 35 (80% power), 47 (90% power)
 50% of observed effect: n per arm = 79 (80% power), 106 (90% power)
power.t.test: 20.7 
Simulated power at n = 20 per arm: 0.788 (20000 replicates)

The simulation draws many sets of group means and variances at the planned sample size and counts how often the two-sample t-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

14. Analyses Reported by the Sponsor

The registry reports the trial’s primary analysis as a nonparametric ANCOVA model comparing the placebo and Serostim® 4 mg groups, with p < 0.001. It does not report the model’s adjusted estimate or confidence interval in the posted analysis. That reported p-value should be distinguished from the unadjusted recalculation based on the posted group means, counts, and standard deviations.

The recalculated mean difference is -33.1 square centimeters, with a 95% confidence interval from -42.48 to -23.72. It is a simple summary-statistic comparison, not a reproduction of the registry’s nonparametric ANCOVA. Differences in adjustment and statistical method mean the two results answer closely related but not identical statistical questions. The recalculation helps describe the contrast’s scale and uncertainty; it does not supersede the sponsor’s own analysis.

The registry record does not report enough detail to reconstruct the sponsor’s model, including its covariates and full specification. For that reason, the sponsor-reported result and the recalculated result should be presented with their methods clearly separated. The record does not indicate a discrepancy between the posted and recalculated result, but the absence of a reported adjusted estimate still limits direct comparison of their effect sizes and intervals.

15. Multiplicity, Missing Data and Analysis Populations

The registry lists a primary endpoint and four secondary outcomes. It reports one primary analysis, using a nonparametric ANCOVA model, but does not report a multiplicity adjustment, testing hierarchy, or strategy for controlling the family-wise error rate across endpoints. When several hypotheses are tested, chance findings become more likely if each is judged at the same threshold without adjustment. This general concern is why isolated secondary p-values should not be interpreted with the same confirmatory weight as a prespecified primary comparison.

The primary outcome population is defined as a modified ITT population: subjects with a baseline and at least one post-baseline efficacy measurement in Treatment Period I who were evaluable for the endpoint. This is a stated analysis-population definition, but it does not reveal how missing values were handled or what assumptions were made about participants without post-baseline measurements. The reasons for missing endpoint data and the amount of missingness by randomized group are not reported in the registry record.

The registry provides analyzed counts for the primary endpoint, but does not describe whether any imputation, sensitivity analysis, or alternative missing-data method was used. It also does not report whether the primary analysis followed the randomized assignment regardless of treatment adherence, or how protocol deviations were handled. These details matter because missing outcomes or exclusions can affect how well a comparison retains the protection of randomization.

The reported primary method is named, but its detailed model specification, covariates, and diagnostics are not reported. The registry does not report the protocol’s original statistical analysis plan, interim analyses, or a sample-size justification. Those absences do not invalidate the posted result, but they limit independent assessment of whether all analytic decisions were prespecified and how robust the findings are to alternative choices. The available record supports a focused interpretation of the posted primary comparison, with caution about broader claims from secondary outcomes or unreported sensitivity analyses.

16. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: pneumonia (1.4%), groin abscess (1.4%), basal cell carcinoma (1.4%), depression (1.2%), abdominal pain (1.2%).

The registry reports serious adverse events and other adverse events separately for treatment periods and groups. In Period I, serious adverse events affected 2 of 81 participants at risk in the placebo group and 3 of 244 at risk in the Serostim® 4 mg group. The “other adverse events” counts were 70 of 81 and 244 of 244, respectively. These are counts within the registry’s stated at-risk groups, not estimates adjusted for exposure time or other differences between participants.

For Period II, the record lists 3 of 93 serious adverse events and 46 of 93 other adverse events for the Serostim® 4 mg to placebo sequence, and 2 of 92 serious adverse events and 48 of 92 other adverse events for the Serostim® 4 mg to Serostim® 2 mg sequence. For the placebo-to-placebo period, 2 of 73 serious adverse events and 14 of 73 other adverse events are listed; for the subsequent placebo-to-Serostim® 4 mg period, 1 of 73 serious adverse events and 73 of 73 other adverse events are listed.

The registry lists serious adverse event terms and percentages, including pneumonia, groin abscess, basal cell carcinoma, depression, abdominal pain, and diarrhoea. Death counts are not reported in the registry record. These summaries describe reported events; they do not establish causation or provide a complete comparative safety assessment. Period II sequences and periods differ, so their counts should not be pooled or directly compared without accounting for treatment exposure and study design.

17. What the Result Does, and Does Not, Mean

The primary result describes a Week 12 difference in mean change in CT-measured VAT between the analyzed placebo and Serostim® groups. The Serostim® group’s mean change was -32.6 square centimeters, compared with 0.5 for placebo; the unadjusted mean difference was -33.1. The registry’s own analysis reports p < 0.001. Together, these findings indicate a statistically clear between-group contrast for this measured endpoint under the reported analysis.

That conclusion is bounded by what was measured. VAT area is one component of abdominal fat distribution, not a direct summary of every feature of HIV-associated adipose redistribution syndrome. A result for VAT does not establish a corresponding result for trunk fat, patient-reported distress, cholesterol, or other outcomes. Those outcomes are reported separately and should be considered on their own terms.

The result also does not establish how durable the Week 12 difference was after the primary comparison, how participants fared under the later Period II treatment sequences, or whether the observed magnitude meets a threshold that matters to patients. The registry record does not report a threshold for clinical importance. Nor does a group mean say that all participants changed in the same direction or by a similar amount.

Statistical evidence is not identical to clinical importance. The p-value addresses how compatible the data are with a null comparison under the sponsor’s analysis assumptions; the effect estimate and confidence interval describe the contrast and its statistical precision in the unadjusted recalculation. Neither supplies missing context about patient priorities, longer-term outcomes, or the balance of benefits and harms. The safety summaries also require cautious interpretation because reported event counts do not by themselves establish causation or a complete comparative risk profile.

The defensible reading is therefore specific: the posted results show a lower average Week 12 VAT change in the Serostim® group than in the placebo group among participants evaluable for this endpoint, and the registry’s primary analysis reports a statistically significant comparison. Broader conclusions about lasting effects, overall clinical benefit, or the experience of every participant are not established by this endpoint alone.

18. Why This Trial Matters Statistically

This trial illustrates why a clinical result should be read through several statistical layers rather than through a p-value alone. The primary endpoint is a continuous imaging measure, the groups have different analyzed counts, and the participant-level standard deviations are sizable. Looking at the means, contrast, interval, and sponsor-reported model result together gives a fuller account than treating statistical significance as a complete interpretation.

It also demonstrates the distinction between a trial’s own analysis and an unadjusted recalculation from summary statistics. The registry reports a nonparametric ANCOVA and p < 0.001, whereas the recalculated difference and confidence interval describe a simple comparison of posted group summaries. Recognizing that distinction helps prevent an independently calculated interval from being mistaken for the sponsor’s adjusted estimate.

The study’s additional endpoints create another important statistical lesson. Several outcomes can provide a broader view of measured domains, but multiple testing and differing endpoint meanings make a simple count of “positive” and “negative” results misleading. The primary endpoint has a defined confirmatory role; secondary results require attention to multiplicity, prespecification, missingness, and clinical context.

Finally, the planning illustrations show how sample-size requirements depend on the effect a future study aims to detect. Smaller target effects require more participants under the stated assumptions. These illustrations are not the original design rationale and should not be interpreted as observed power. Together, these considerations make the record useful for learning how estimation, model-based inference, analysis populations, and planning assumptions shape the interpretation of a clinical trial.

19. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The registry record leaves several trial-specific limitations unresolved. The primary analysis is identified as nonparametric ANCOVA, but the detailed model, covariates, diagnostics, and adjusted effect estimate are not reported. The recalculated estimate and confidence interval are unadjusted, so they cannot supply the missing model-based estimate. Direct assessment of the sponsor’s adjustment and its influence on the result is therefore limited.

The primary endpoint analysis included 74 placebo participants and 210 Serostim® participants, while total enrollment was 326. The reasons for the outcome-specific analyzed counts and any differences between randomized and analyzed populations are not reported in the registry record. Missing-data handling, sensitivity analyses, adherence information, and protocol deviations are also not reported. These omissions limit assessment of potential selection effects and robustness.

The registry does not report the original sample-size calculation or design assumptions, allocation ratio, randomization sequence methods, detailed masking procedures, or a statistical analysis plan. It also does not report an interim-analysis plan or a multiplicity strategy for the secondary endpoints. These omissions restrict evaluation of prespecification and the context for inferential decisions.

The primary comparison is at Week 12, and the endpoint is a CT-based VAT measure. The record does not supply a clinically important difference threshold or establish how long the observed difference persisted. Later treatment sequences have different regimens and follow-up periods, so they should not be treated as a continuation of the same primary randomized comparison. Safety counts are reported by periods and sequences, but the record does not give a full causal assessment or detailed exposure-adjusted comparisons. These limitations call for a narrow interpretation of the posted endpoint rather than extrapolation to unreported outcomes or longer-term effects.

20. Related Tutorials

21. Related Statistical Calculators

22. Sources

• ClinicalTrials.gov: Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients — NCT00082628.
• Registry record last updated 2018-07-20; status last verified 2017-09.
• Results first posted 2018-07-20.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

23. Record Summary

NCT00082628 is a completed Phase III, randomized, double-blind, placebo-controlled, parallel-group study sponsored by EMD Serono, with enrollment of 326. Treatment Period I compared daily placebo with Serostim® 4 mg for 12 weeks. The primary endpoint was change from baseline in absolute VAT area at Week 12, measured by CT scan at L4-5.

For the modified ITT population evaluable for the primary outcome, the posted mean changes were 0.5 for placebo and -32.6 for Serostim® 4 mg. The unadjusted recalculated mean difference was -33.1, with a 95% confidence interval from -42.48 to -23.72. The registry reports a nonparametric ANCOVA analysis with p < 0.001. Secondary outcomes cover trunk fat, body image distress, non-HDL cholesterol, and a later VAT-based failure outcome. The registry record does not report several details needed for fuller assessment, including missing-data methods, multiplicity handling, and the original sample-size justification.